News & Insights
Aeirtec granted patent on second aspect of high sensitivity multiplexing proteomics technology
Aeirtec granted patent on second aspect of high sensitivity multiplexing proteomics technology
February 2023
Aeirtec granted patent on second aspect of high sensitivity multiplexing proteomics technology
As part of Aeirtec’s PCT application across North America, Europe and China, the UK patent office has granted the patent on a second aspect of Aeirtec’s high sensitivity multiplexing proteomics technology
November 2021
Aeirtec commences collaboration on Respiratory Infection diagnostics with virologists at Lancaster University, UK
October 2021
Assignment of multiplexing patent to Aeirtec
The patent issued to Aeirtec’s and partner’s subsidiary in 2018 has been fully re-assigned to Aeirtec
July 2020
Second aspect of high assay sensitivity patent filing
Aeirtec files a patent application on a second aspect of high assay sensitivity
February 2017
Aeirtec develops 'Universal Immunoassay Buffer'
MRC funding for MASTERPLANS consortium
July 2014
Aeirtec has developed a universal immunoassay buffer for use in capture and detection stages, improving sensitivity and minimising both nonspecific binding and heterophilic antibody activity.
Aeirtec and Manchester University present data from marker multiplex profiling in SLE at the Amercian College of Rheumatology (ACR) meeting 11th -16th November in Washington DC. Title: High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE.
Aeirtec and Manchester University have received funding from BBSRC for studies toward innovation in immunoassay technology.
To support molecular pathology, the MRC and EPSRC have supported six nodes led by the universities of Edinburgh, Glasgow, Leicester, Manchester, Newcastle and Nottingham. Each node brings researchers, clinicians and industry together to develop molecular diagnostic tools, to enable disease stratification. Aeirtec is a member of the Manchester-led node and the focus of this node is on rheumatoid arthritis, psoriasis and lupus.
The Manchester University led MASTERPLANS consortium, of which Aeirtec is a member, have been awarded a £4.2m fund by the UK Medical Research Council (MRC) for stratification of patients with system lupus erythematosus (SLE) according to treatment response. Aeirtec will provide high sensitivity multiplex analysis of markers in patients' samples to identify marker patterns within the stratification.
Aeirtec have recieved funding from Tenovus Cancer Care within a collborative project to examine immune/inflammatory markers in cancer patients.
October 2021
Assignment of multiplexing patent to Aeirtec
February 2015
Aeirtec receives funding from the Tenovus Cancer Care charity.
October 2016
BBSRC funding.
November 2016
Aeirtec and Manchester University present at the ACR.
July 2015
MRC and EPSRC funding for Manchester Molecular Pathology Node
The patent issued to Aeirtec’s and partner’s subsidiary in 2018 has been fully re-assigned to Aeirtec
October 2023
Aeirtec commences development of antibodies for immunoassay that avoid heterophylic activity
As part of evolution within Aeirtec’s high sensitivity multiplexing proteomics technology, Aeirtec has generated a facility for recombinant antibody production